View all results
No results
News
Events
The industry
Industry overview
Industrial biotech
Swiss Biotech Report
Success Stories
Company directory
Jobs
Talent platform
Networking platforms
Newsletter
Association
Our mission
Members
Academy
Insight Events
Partners
Team
Media
Add listing
Log in
or
Register
0
Add listing
anti-HERV-W products
Product
prev
next
Leave a review
Claim listing
Bookmark
Share
Report
prev
next
Indicaton
ALS
Therapeutic indications
CNS
Company
GeNeuro SA
You may also be interested in
Dipraglurant (mGlu5 NAM) for PD-LID
Milestone: Indication under evaluation Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).
Featured
Phase II started
GABAb PAM for Chronic cough
We plan to develop our GABAB PAM drug candidate for the treatment of chronic cough. This target is clinically validated with baclofen, an orthosteric agonist of GABAB, is used off label to treat chronic cough patients. However, baclofen’s use is limited by serious side-effects, short half-life and gradual loss of efficacy during chronic treatment. By more precisely targeting the GABAB receptor with a PAM we aim to have a best-in-class treatment with improved tolerability suitable for the chronic nature of this disease. This indication has a significant unmet medical need and represents a solid commercial opportunity. We are in late clinical candidate selection phase and have demonstrated proof-of-concept in animal models of cough with several compounds. Subject to funding, we expect IND enabling studies to begin in 2024.
Featured
Discovery
Dipraglurant (mGlu5 NAM) for POST-STROKE / TBI SENSORIMOTOR RECOVERY
Dipraglurant is a metabotropic glutamate receptor subtype 5 negative allosteric modulator, or mGlu5 NAM, that we are developing for post-stroke sensorimotor recovery. According to the World Stroke Organization (www.world-stroke.org), over there are 12.2 million strokes each year globally which can lead to motor paralysis, loss of sensory function, impaired autonomic functions such as bladder/bowel control, impaired cognition leading to deficits in communication, attention and memory, and accompanied by pain. There are currently no drugs to support sensorimotor recovery and current therapies rely on retraining and physiotherapy, with rehabilitation, largely partial, taking 6 month or more. Functional recovery by stimulating network connectivity in the brain has been demonstrated post-stroke preclinically with dipraglurant which significantly restored functional control after just three days of once-daily treatment. We are conducting additional in vivo studies with dipraglurant in animal models of stroke and subject to funding, we plan to commence a Phase 2a study in 2024.There is a large unmet need in post-stroke sensorimotor recovery, and we believe this innovative approach represents a significant commercial opportunity. We are also investigating dipraglurant’s suitability for traumatic brain injury, or TBI, recovery, where we believe the mechanism of action would be similar to stroke recovery and where the fast onset could be advantageous
Featured
Phase II started
Cart
×
View all results
No results
Facebook
X
WhatsApp
Telegram
Pinterest
LinkedIn
Tumblr
Reddit
VKontakte
Mail
Copy link
Share via...
This site uses cookies:
Find out more.
Accept